Patients with major depression had faster transitions to both early and later stages of cardiovascular disease than patients without major depression.
The authors used medical loss ratio forms to assess trends in premiums, medical claims, administrative costs, quality improvement, and margins in the large group insurer market.
Analysis of insurance claims reveals that criteria other than the Healthcare Effectiveness Data and Information Set (HEDIS) persistent asthma definition can identify more at-risk patients with reasonable loss of specificity.
Although currently underutilized, granulocyte colony-stimulating factor prophylaxis as supportive cancer care provides substantial value to society. Aligning utilization with clinical guidelines would increase this value considerably.
Electronic health record (EHR)-based comorbidity assessment had low sensitivity for identifying major comorbidities and poorly predicted survival. EHR-based comorbidity data require validation prior to application to risk adjustment.
Patients who obtained authorization but did not get initial mental health treatment needed treatment as much as or more than patients who presented for care.
This article provides an overview of the impact of specialty care and the opportunity for it to leapfrog primary care as a lead focus for accountable care.
This article describes the development and capabilities of a Webbased decision support system for care managers working in the context of the chronic care model.
A reimbursement strategy for collaborative care models is presented to enhance access to integrated behavioral healthcare for children and adolescents from underserved areas.
Authors from The Brookings Institution update their recommendations by focusing on 3 concrete objectives to slow spending and improve quality of care within the next 5 years.
The availability of biosimilar products may improve access to healthcare by increasing the number of therapeutic options available at potentially lower costs. As of April 2019, 18 such biological products had been approved by the FDA, including 4 biosimilars for trastuzumab, 3 each for infliximab and adalimumab, 2 each for pegfilgrastim and filgrastim, and 1 each for rituximab, epoetin alfa, bevacizumab, and etanercept. The pace of approvals has accelerated, from the first indication for a filgrastim biosimilar in 2015 to 3 approvals in 2016, 5 in 2017, and 9 through early 2019, 7 of which were announced in the 2018 calendar year.
Hospital and physician-hospital alignment, but not loyalty, are predictors of integrated electronic health record adoption by admitting physicians in an integrated system.
Self-empowering team resource management, when aided by information technology, appears to help reduce adverse drug events in primary care offices.
A continuous quality improvement program, based on Lean concepts and including architectural, managerial, and organizational features, allows the emptying of emergency department corridors and the improvement of time interval measurements/quality indicators.